European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2012
NCT01460160
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib